v3.25.3
Fair value measurement - Contingent Consideration (Details)
$ in Thousands, € in Millions
9 Months Ended 12 Months Ended
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Sep. 30, 2025
EUR (€)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Contingent consideration $ 17,754   $ 10,860  
Changes in fair value of contingent consideration $ 5,293 $ (2,032)    
One hundred percent likelihood of AMT-260 advancing into clinical development        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Percentage of increase in Probability of Success 100.00%      
Changes in fair value of contingent consideration $ 57,200      
uniQure France [S.A.S]        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Contingent consideration 17,754   $ 10,860  
Changes in fair value of contingent consideration 5,293      
uniQure France [S.A.S] | Maximum        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Contingent consideration payable upon achievement of contractually defined milestones $ 167,900     € 143.1
Contingent consideration discount rate percentage 12.50%   16.20%  
uniQure France [S.A.S] | Minimum        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]        
Contingent consideration discount rate percentage 12.10%   15.30%